The next-generation combination drugs as part of the comprehensive therapy for inflammatory diseases of the pharynx

Abstract

Inflammatory diseases of the pharynx constitute one of the most significant nosologies groups in the ENT organ diseases profile. According to modern epidemiological data, acute and chronic tonsillopharyngitis are inferior only to influenza and other forms of ARVI with predominantly nasal and paranasal sinuses, as well as the lower respiratory tract inflammation in prevalence among the population. Infectious pathogens are the most common etiology of inflammatory diseases of the pharynx. Accordingly, the pharmacological agents should be selected among the drugs having pronounced antimicrobial activity against both bacterial and other organisms - viral and fungal, and an analgesic effect, as sore throat is the main symptom of tonsillofingitis. The combination preparation Septolete® total is one of such drugs.

Keywords

• inflammatory diseases of the pharynx
• local antiseptics
• septolete® total